Clinical Categorization Algorithm (CLICAL) and Machine Learning Approach (SRF-CLICAL) to Predict Clinical Benefit to Immunotherapy in Metastatic Melanoma Patients: Real-World Evidence from the Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Clinical Categorization Algorithm (CLICAL) and Machine Learning Approach (SRF-CLICAL) to Predict Clinical Benefit to Immunotherapy in Metastatic Melanoma Patients: Real-World Evidence from the Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy
Authors
Keywords
-
Journal
Cancers
Volume 13, Issue 16, Pages 4164
Publisher
MDPI AG
Online
2021-08-19
DOI
10.3390/cancers13164164
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- No Impact of NRAS Mutation on Features of Primary and Metastatic Melanoma or on Outcomes of Checkpoint Inhibitor Immunotherapy: An Italian Melanoma Intergroup (IMI) Study
- (2021) Michele Guida et al. Cancers
- Looking into a Better Future: Novel Therapies for Metastatic Melanoma
- (2021) Alessia Villani et al. Dermatology and Therapy
- Impact of modern systemic therapies and clinical markers on treatment outcome for metastatic melanoma in a real‐world setting
- (2020) I. Krakowski et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Frequency of circulating CD8+CD73+T cells is associated with survival in nivolumab-treated melanoma patients
- (2020) Mariaelena Capone et al. Journal of Translational Medicine
- Quality of life in long-term survivors of advanced melanoma treated with checkpoint inhibitors
- (2020) Maha Mamoor et al. Journal for ImmunoTherapy of Cancer
- Author Correction: Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma
- (2020) David Liu et al. NATURE MEDICINE
- Recent success and limitations of immune checkpoint inhibitors for cancer: a lesson from melanoma
- (2019) Margaret Ottaviano et al. VIRCHOWS ARCHIV
- The real-world impact of modern treatments on the survival of patients with metastatic melanoma
- (2019) Marco Donia et al. EUROPEAN JOURNAL OF CANCER
- First-line therapy-stratified survival in BRAF-mutant melanoma: a retrospective multicenter analysis
- (2019) Bastian Schilling et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Current and emerging systemic therapies for cutaneous metastatic melanoma
- (2019) Robert Mason et al. EXPERT OPINION ON PHARMACOTHERAPY
- Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop
- (2019) Davide Bedognetti et al. Journal for ImmunoTherapy of Cancer
- Long-Term Survival, Quality of Life, and Psychosocial Outcomes in Advanced Melanoma Patients Treated with Immune Checkpoint Inhibitors
- (2019) Anne Rogiers et al. Journal of Oncology
- Automatic discovery of image-based signatures for ipilimumab response prediction in malignant melanoma
- (2019) Nathalie Harder et al. Scientific Reports
- Sustained Type I interferon signaling as a mechanism of resistance to PD-1 blockade
- (2019) Nicolas Jacquelot et al. CELL RESEARCH
- ErbB3 Phosphorylation as Central Event in Adaptive Resistance to Targeted Therapy in Metastatic Melanoma: Early Detection in CTCs during Therapy and Insights into Regulation by Autocrine Neuregulin
- (2019) Ciro Francesco Ruggiero et al. Cancers
- Real‐world survival of patients with advanced BRAF V600 mutated melanoma treated with front‐line BRAF/MEK inhibitors, anti‐PD‐1 antibodies, or nivolumab/ipilimumab
- (2019) Justin C. Moser et al. Cancer Medicine
- Robust immunoscore model to predict the response to anti-PD1 therapy in melanoma
- (2019) Run-Cong Nie et al. Aging-US
- Overall Survival in Patients With Advanced Melanoma Who Received Nivolumab Versus Investigator’s Choice Chemotherapy in CheckMate 037: A Randomized, Controlled, Open-Label Phase III Trial
- (2018) James Larkin et al. JOURNAL OF CLINICAL ONCOLOGY
- Pan-cancer adaptive immune resistance as defined by the Tumor Inflammation Signature (TIS): results from The Cancer Genome Atlas (TCGA)
- (2018) Patrick Danaher et al. Journal for ImmunoTherapy of Cancer
- Impact of clinicopathological characteristics on survival in patients treated with immune checkpoint inhibitors for metastatic melanoma
- (2018) Bin Zhao et al. INTERNATIONAL JOURNAL OF CANCER
- Patient-reported outcomes in KEYNOTE-006, a randomised study of pembrolizumab versus ipilimumab in patients with advanced melanoma
- (2017) Teresa M. Petrella et al. EUROPEAN JOURNAL OF CANCER
- Health-related quality of life results from the phase III CheckMate 067 study
- (2017) Dirk Schadendorf et al. EUROPEAN JOURNAL OF CANCER
- IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade
- (2017) Mark Ayers et al. JOURNAL OF CLINICAL INVESTIGATION
- Sequencing Treatment in BRAFV600 Mutant Melanoma
- (2017) Douglas B. Johnson et al. JOURNAL OF IMMUNOTHERAPY
- Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006)
- (2017) Jacob Schachter et al. LANCET
- Targeted agents and immunotherapies: optimizing outcomes in melanoma
- (2017) Jason J. Luke et al. Nature Reviews Clinical Oncology
- PD-L1 expression with immune-infiltrate evaluation and outcome prediction in melanoma patients treated with ipilimumab
- (2017) Gabriele Madonna et al. OncoImmunology
- Serum exosomes as predictors of clinical response to ipilimumab in metastatic melanoma
- (2017) Marco Tucci et al. OncoImmunology
- Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab
- (2016) Benjamin Weide et al. CLINICAL CANCER RESEARCH
- Health-related quality of life in the randomised KEYNOTE-002 study of pembrolizumab versus chemotherapy in patients with ipilimumab-refractory melanoma
- (2016) Dirk Schadendorf et al. EUROPEAN JOURNAL OF CANCER
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Evaluating Random Forests for Survival Analysis Using Prediction Error Curves
- (2015) Ulla B. Mogensen et al. Journal of Statistical Software
- What have we learned from cancer immunotherapy in the last 3 years?
- (2014) Paolo A Ascierto et al. Journal of Translational Medicine
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
- (2009) J. D. Wolchok et al. CLINICAL CANCER RESEARCH
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started